layer can lead to thrombosis.

e inhibition of cellular proliferation by a er intracoronary stenting with drug-eluting stents, similar to bare metal 503
paclitaxel and sirolimus or derivatives not only a ects vascular smooth stents. Evidence for the bene t of even longer periods is limited.
muscle cell proliferation but also attenuates the formation of an intact
endothelial layer within the stented artery and thereby markedly reduces Acknowledgment: omas Michel and Brian B. Ho man contributed to
the rate of restenosis compared with bare metal stents. Dual antiplatelet this chapter in recent editions of this book. We have retained some of their
therapy (aspirin, typically with clopidogrel) is recommended for one year text in the current edition.

Drug Facts for Your Personal Formulary: Coronary Artery Disease

Drug erapeutic Uses Major Toxicity and Clinical Pearls
Organic Nitrates
Glyceryl trinitrate (GTN, ⇒
nitroglycerin) preload reduction without steal e ect
Isosorbide dinitrate
(ISDN) 2+
channel blockers
Isosorbide mononitrate
(ISMN)

SECTION III MODULATION OF PULMONARY, RENAL, AND CARDIOVASCULAR FUNCTION

Molsidomine

Inhaled NO
neonates
Ca2+ Channel Blockers
Dihydropyridines ⇒
Amlodipine

Lercanidipine
hypotension and trigger angina
Nitrendipine ↓ heart rate and AV conduction; should not be used with
Others β blockers

Verapamil
β Blockers
Atenolol
Bisoprolol

Metoprolol
Nadolol

Many others migraine, etc.)

Ranolazine
+
and other cardiac ion currents

Ivabradine
↓

Nicorandil
-stimulatory action
KATP
↓
 504
Drug Facts for Your Personal Formulary: Coronary Artery Disease (continued)
Drug erapeutic Uses Major Toxicity and Clinical Pearls
Trimetazidine
Antiplatelet, Anti-integrin, and Antithrombotic Drugs
Aspirin ↓ 2
receptor (MI, stroke) receptor antagonists)
antagonists
(clopidogrel,
prasugrel, ticagrelor
cangrelor [IV])
CHAPTER 27 TREATMENT OF ISCHEMIC HEART DISEASE
Low-molecular-weight
heparins (e.g.,
t
Lepirudin
recombinant lepirudin
Bibliography
Amsterdam EA, et al. 2014 AHA/ACC guideline for the management of
patients with non-ST-elevation acute coronary syndromes: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64:e139–e228.
Angus JA, et al. Quantitative analysis of vascular to cardiac selectivity of
L- and T-type voltage-operated calcium channel antagonists in human
tissues. Clin Exp Pharmacol Physiol, 2000, 27:1019–1021.
Ardehali H, O’Rourke B. Mitochondrial K(ATP) channels in cell survival
and death. J Mol Cell Cardiol, 2005, 39:7–16.
Bainbridge AD, et al. A comparative assessment of amlodipine and
felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J
Clin Pharmacol, 1993, 45:425–430.
Bangalore S, et al. Clinical outcomes with beta-blockers for myocardial
infarction: a meta-analysis of randomized trials. Am J Med, 2014,
127:939–953.
Barbato E, et al. Long-term e ect of molsidomine, a direct nitric oxide
donor, as an add-on treatment, on endothelial dysfunction in patients
with stable angina pectoris undergoing percutaneous coronary
intervention: results of the MEDCOR trial. Atherosclerosis, 2015,
240:351–354.
Bedenis R, et al. Cilostazol for intermittent claudication. Cochrane
Database Syst Rev, 2014, (10):CD003748.
Belardinelli L, et al. Inhibition of the late sodium current as a potential
cardioprotective principle: e ects of the late sodium current inhibitor
ranolazine. Heart, 2006, 92:iv6-iv14.
production (aspirin) or ADP receptors
Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for
the prevention of atherothrombotic events. N Engl J Med, 2006,
354:1706–1717.
Billinger M, et al. Collateral and collateral-adjacent hyperemic
vascular resistance changes and the ipsilateral coronary ow reserve.
Documentation of a mechanism causing coronary steal in patients
with coronary artery disease. Cardiovasc Res, 2001, 49:600–608.
Bloch KD, et al. Inhaled NO as a therapeutic agent. Cardiovasc Res, 2007,
75:339–348.
Bodi V, et al. Prognostic value of dipyridamole stress cardiovascular
magnetic resonance imaging in patients with known or suspected
coronary artery disease. J Am Coll Cardiol, 2007, 50:1174–1179.
Boulinguez S, et al. Giant buccal aphthosis caused by nicorandil [in
French]. Presse Med, 1997, 26:558.
Brown BG, et al. e mechanisms of nitroglycerin action: stenosis
vasodilatation as a major component of the drug response. Circulation,
1981, 64:1089–1097.
Burnett AL, et al. Nitric oxide: a physiologic mediator of penile erection.
Science, 1992, 257:401–403.
Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients
with a planned invasive strategy for acute coronary syndromes
(PLATO): a randomised double-blind study. Lancet, 2010, 375:283–293.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel
versus aspirin in patients at risk of ischaemic events (CAPRIE).
CAPRIE Steering Committee. Lancet, 1996, 348:1329–1339.
Cheitlin MD, et al. ACC/AHA expert consensus document. Use of
sildena l (Viagra) in patients with cardiovascular disease. American